SUPN News and Press, Supernus Pharmaceuticals Inc. From 02/28/23

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2022 Earnings Conference Call February 28, 2023, 04:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants David Amsellem - Piper Sandler Andre...

Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q4 GAAP EPS of $0.43. Revenue of $167.33M (+5.2% Y/Y). Sees FY 2023 revenue of $580M to $620M. The consensus estimate is $601.21M. For further details see: Supernus Pharmaceuticals reports Q4 results, sees ...

Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021 Fourth quarter 2022 Qelbree ® net product sales of $23.6 million increased 29% compared to third quarter of 2022; Full year 2022 Qelbree net product sales of $61.3 million, compared to $9.9 m...

Supernus Pharmaceuticals ( NASDAQ: SUPN ) said Tuesday it entered into a $150 million credit line agreement with UBS Bank USA, which can be drawn at any time. Any fixed rate borrowing will bear interest at a fixed interest rate, equal to the sum of the UBS Fixed Funding Rate plus ...

ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it entered into a credit line agreement (the ...

Summary Heading into Q4, 2022 earnings, Supernus is pulling back after its strong post-Q3, 2022 run. Supernus TROKENDI XR patent cliff is top of mind as 2023 unfolds. Q4, 2022 earnings should be particularly interesting for shareholders. Supernus (SUPN) is a mature CNS the...

ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial ...

Summary A number of VBR "green energy" picks have popped higher in January, pulling investment returns for the group of past picks strongly higher. A performance review of 46 previous selections since late June is discussed. I continue to refine the search and formula ideas for iden...

ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of...

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2022 Earnings Conference Call November 8, 2022 4:30 P.M. ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Cal...